Curr Hematol Malig Rep (2012) 7:133–143 92. Baldus CD, Thibaut J, Goekbuget N, et al. Prognostic implica- tions of NOTCH1 and FBXW7 mutations in adult acute T- lymphoblastic leukemia. Haematologica. 2009;94:1383–90. 93. Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblas- tic leukemia. Blood. 2009;114:647–50. 94. Yamada Y, Hatta Y, Murata K, et al. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol. 1997;15:1778–85. 95. Fizzotti M, Cimino G, Pisegna S, et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood. 1995;85:2685–90. 143 96. Markaki EA, Stiakaki E, Zafiropoulos A, et al. Mutational analysis of the cell cycle inhibitor Kip1/p27 in childhood leukemia. Pediatr Blood Cancer. 2006;47:14–21. 97. Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in T- ALL. Blood. 2009;114:1038–45. 98. Renneville A, Kaltenbach S, Clappier E, et al. Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies. Leukemia. 2010;24:476–80. 99. Gutierrez A, Sanda T, Ma W, et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010;115:2845–51. 100. Kleppe M, Soulier J, Asnafi V, et al. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood. 2011;117:7090–8.